18F-alfatide II and 18F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy

Journal of Nuclear Medicine

Volumn 55, Issue 1, 2014, Pages 154-160

  Guo, Jinxia ^a,b,c   Guo, Ning ^b,c   Lang, Lixin ^b   Kiesewetter, Dale O ^b   Xie, Qingguo ^a   Li, Quanzheng ^d   Eden, Henry S ^b   Niu, Gang ^b   Chen, Xiaoyuan ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c XIAMEN UNIVERSITY   (China)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Dual tracer dynamic PET; Parametric imaging; Therapy response

Indexed keywords

ALFATIDE F 18; DOXORUBICIN; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; PACLITAXEL; UNCLASSIFIED DRUG; ALBUMIN BOUND PACLITAXEL; ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ALFATIDE II; ANTINEOPLASTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; CYCLOPEPTIDE; DIAGNOSTIC AGENT; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL MONITORING; CANCER CHEMOTHERAPY; CANCER SIZE; CELL STRAIN; CELL STRAIN U87MG; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG TRANSPORT; DRUG TUMOR LEVEL; EARLY DIAGNOSIS; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NEOPLASM; NONHUMAN; NUDE MOUSE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RADIOACTIVITY; RADIOLOGICAL PARAMETERS; TREATMENT RESPONSE; TUMOR VASCULARIZATION; 18F-ALFATIDE II; 18F-FDG; ANIMAL; DUAL-TRACER DYNAMIC PET; PARAMETRIC IMAGING; SCINTISCANNING; TIME;

18F-ALFATIDE II; 18F-FDG; DUAL-TRACER DYNAMIC PET; PARAMETRIC IMAGING; THERAPY RESPONSE;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MICE; MICE, NUDE; NEOPLASMS; OLIGOPEPTIDES; PACLITAXEL; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TIME FACTORS;

EID: 84894877870     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.122069     Document Type: Article

References (36)

1. Jones T. The imaging science of positron emission tomography. Eur J Nucl Med. 1996;23: 807-813.
2. Niu G, Chen X. Apoptosis imaging: beyond annexin V. J Nucl Med. 2010;51: 1659-1662.
3. Kubota K, Ishiwata K, Kubota R, et al. Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67. J Nucl Med. 1991;32: 2118-2123.
4. 18F]fluoroerythronitroimidazole PET. J Nucl Med. 2001;42: 1643-1652.
5. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med. 2004;45: 1829-1837.
6. 18F-FDG PET of response to Abraxane therapy. J Nucl Med. 2011;52: 140-146.
7. Yang M, Gao H, Yan Y, et al. PET imaging of early response to the tyrosine kinase inhibitor ZD4190. Eur J Nucl Med Mol Imaging. 2011;38: 1237-1247.
8. Yang M, Gao H, Sun X, et al. Multiplexed PET probes for imaging breast cancer early response to VEGF121/rGel treatment. Mol Pharm. 2011;8: 621-628.
9. 3 integrin expression. Mol Imaging Biol. 2010;12: 530-538.
10. 68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem. 2011;22: 2415-2422.
11. 68Ga]Ga-NOTA-PRGD2 using a reference tissue model. PLoS ONE. 2012;7: e37506.
12. 18F-AlFNOTA-PRGD2. Eur J Nucl Med Mol Imaging. 2012;39: 683-692.
13. 18FFDG and secondary shorter-lived tracers. IEEE Trans Nucl Sci. 2009;56: 2750-2758.
14. Black NF, McJames S, Rust TC, Kadrmas DJ. Evaluation of rapid dual-Tracer 62Cu-PTSM 1 62Cu-ATSM PET in dogs with spontaneously occurring tumors. Phys Med Biol. 2008;53: 217-232.
15. Kearfott KJ. Feasibility of simultaneous and sequentially administered dual tracer protocols for measurement of regional cerebral haematocrit using positron emission tomography. Phys Med Biol. 1990;35: 249-258.
16. 11C]tracer single-Acquisition positron emission tomography studies. J Cereb Blood Flow Metab. 2001;21: 1480-1492.
17. Rust TC, Kadrmas DJ. Rapid dual-Tracer PTSM1ATSM PET imaging of tumour blood flow and hypoxia: a simulation study. Phys Med Biol. 2006;51: 61-75.
18. Fakhri GE. Ready for prime time? Dual tracer PET and SPECT imaging. Am J Nucl Med Mol Imaging. 2012;2: 415-417.
19. 18F-labeled monomeric and dimeric RGD peptides using compartment model. Mol Imaging Biol. 2012;14: 743-752.
20. 18F-AlF-NOTA-RGD tracers. Mol Imaging Biol. August 28, 2013 [Epub ahead of print].
21. 18F]AlF-NOTA analog of exendin-4 for imaging of GLP-1 receptor in insulinoma. Theranostics. 2012;2: 999-1009.
22. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
23. 18F-FPRGD4). J Nucl Med. 2007;48: 1536-1544.
24. Laforest R, Sharp TL, Engelbach JA, et al. Measurement of input functions in rodents: challenges and solutions. Nucl Med Biol. 2005;32: 679-685.
25. Vriens D, de Geus-Oei LF, Oyen WJ, Visser EP. A curve-fitting approach to estimate the arterial plasma input function for the assessment of glucose metabolic rate and response to treatment. J Nucl Med. 2009;50: 1933-1939.
26. Guo H, Renaut RA, Chen K. An input function estimation method for FDG-PET human brain studies. Nucl Med Biol. 2007;34: 483-492.
27. Zheng X, Wen L, Yu SJ, Huang SC, Feng DD. A study of non-invasive Patlak quantification for whole-body dynamic FDG-PET studies of mice. Biomed Signal Process Control. 2012;7: 438-446.
28. Huang SC, Carson RE, Hoffman EJ, Kuhl DE, Phelps ME. An investigation of a double-Tracer technique for positron computerized tomography. J Nucl Med. 1982;23: 816-822.
29. Kadrmas DJ, Rust TC, Hoffman JM. Single-scan dual-Tracer FLT1FDG PET tumor characterization. Phys Med Biol. 2013;58: 429-449.
30. 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med. 2007;48: 602-607.
31. Guo L, Fan L, Pang Z, et al. TRAIL and doxorubicin combination enhances antiglioblastoma effect based on passive tumor targeting of liposomes. J Control Release. 2011;154: 93-102.
32. Albertsson P, Lennernas B, Norrby K. Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sprouting. APMIS. 2003;111: 995-1003.
33. Lee JH, Jang JT, Choi JS, et al. Exchange-coupled magnetic nanoparticles for efficient heat induction. Nat Nanotechnol. 2011;6: 418-422.
34. Kawano K,, Hattori Y, Iwakura H, Akamizu T, Maitani Y. Combination therapy with gefitinib and doxorubicin inhibits tumor growth in transgenic mice with adrenal neuroblastoma. Cancer Med. 2013;2: 286-295.
35. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007; 27: 1533-1539.
36. Eberl S, Anayat AR, Fulton RR, Hooper PK, Fulham MJ. Evaluation of two population-based input functions for quantitative neurological FDG PET studies. Eur J Nucl Med. 1997;24: 299-304.